{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:55:30Z","timestamp":1790999730608,"version":"4.1.0"},"reference-count":39,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,10,2]]},"DOI":"10.1248\/bpb.b26-00306","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:12:00Z","timestamp":1790892720000},"page":"1593-1600","source":"Crossref","is-referenced-by-count":0,"title":["Lipid Nanoparticle-Mediated Vascular-Disrupting Therapy for Lung Metastasis"],"prefix":"10.1248","volume":"49","author":[{"given":"Tomoki","family":"Ueda","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikito","family":"Endo","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sato","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyoshi","family":"Harashima","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Yamada","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"},{"name":"Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920\u20131192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Sultan I, Alfaar AS, Sultan Y, Salman Z, Qaddoumi I. Trends in childhood cancer: incidence and survival analysis over 45 years of SEER data. <i>PLOS ONE<\/i>, <b>20<\/b>, e0314592 (2025).","DOI":"10.1371\/journal.pone.0314592"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Chitapanarux I, Sripan P, Somwangprasert A, Charoentum C, Onchan W, Watcharachan K, Wongmaneerung P, Kongmebhol P, Jia-Mahasap B, Huntrakul L. Stage-specific survival rate of breast cancer patients in northern Thailand in accordance with two different staging systems. <i>Asian Pac. J. Cancer Prev.<\/i>, <b>20<\/b>, 2699\u20132706 (2019).","DOI":"10.31557\/APJCP.2019.20.9.2699"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Emile SH, Horesh N, Garoufalia Z, Oosenbrug M, Boutros M, Wexner SD. A seer-based analysis of survival predictors in stage I colorectal adenocarcinomas. <i>J. Surg. Oncol.<\/i>, <b>132<\/b>, 1320\u20131330 (2025).","DOI":"10.1002\/jso.70111"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Steeg PS. Targeting metastasis. <i>Nat. Rev. Cancer<\/i>, <b>16<\/b>, 201\u2013218 (2016).","DOI":"10.1038\/nrc.2016.25"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. <i>Nat. Rev. Drug Discov.<\/i>, <b>18<\/b>, 197\u2013218 (2019).","DOI":"10.1038\/s41573-018-0007-y"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria J-C. Overcoming resistance to tumor-targeted and immune-targeted therapies. <i>Cancer Discov.<\/i>, <b>11<\/b>, 874\u2013899 (2021).","DOI":"10.1158\/2159-8290.CD-20-1638"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. <i>Nat. Rev. Clin. Oncol.<\/i>, <b>15<\/b>, 81\u201394 (2018).","DOI":"10.1038\/nrclinonc.2017.166"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. <i>Nat. Rev. Drug Discov.<\/i>, <b>15<\/b>, 385\u2013403 (2016).","DOI":"10.1038\/nrd.2015.17"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. <i>Nat. Rev. Cancer<\/i>, <b>8<\/b>, 592\u2013603 (2008).","DOI":"10.1038\/nrc2442"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. <i>Nat. Rev. Cancer<\/i>, <b>17<\/b>, 457\u2013474 (2017).","DOI":"10.1038\/nrc.2017.51"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Smolarczyk R, Czapla J, Jarosz-Biej M, Czerwinski K, Cicho\u0144 T. Vascular disrupting agents in cancer therapy. <i>Eur. J. Pharmacol.<\/i>, <b>891<\/b>, 173692 (2021).","DOI":"10.1016\/j.ejphar.2020.173692"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Gill JH, Rockley KL, De Santis C, Mohamed AK. Vascular disrupting agents in cancer treatment: cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics. <i>Pharmacol. Ther.<\/i>, <b>202<\/b>, 18\u201331 (2019).","DOI":"10.1016\/j.pharmthera.2019.06.001"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. <i>Nucleic Acid Ther.<\/i>, <b>28<\/b>, 146\u2013157 (2018).","DOI":"10.1089\/nat.2018.0721"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Brimacombe CA, Kulkarni JA, Cheng MHY, An K, Witzigmann D, Cullis PR. Rational design of lipid nanoparticles for enabling gene therapies. <i>Mol. Ther. Methods Clin. Dev.<\/i>, <b>33<\/b>, 101518 (2025).","DOI":"10.1016\/j.omtm.2025.101518"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? <i>J. Control. Release<\/i>, <b>244<\/b> (Pt. A), 108\u2013121 (2016).","DOI":"10.1016\/j.jconrel.2016.11.015"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H, Ohga N, Hida K, Harashima H. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system. <i>J. Control. Release<\/i>, <b>173<\/b>, 110\u2013118 (2014).","DOI":"10.1016\/j.jconrel.2013.10.003"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Nakamura T, Miyabe H, Hyodo M, Sato Y, Hayakawa Y, Harashima H. Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. <i>J. Control. Release<\/i>, <b>216<\/b>, 149\u2013157 (2015).","DOI":"10.1016\/j.jconrel.2015.08.026"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Nakamura T, Sato T, Endo R, Sasaki S, Takahashi N, Sato Y, Hyodo M, Hayakawa Y, Harashima H. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis <i>via<\/i> NK cell activation. <i>J. Immunother. Cancer<\/i>, <b>9<\/b>, e002852 (2021).","DOI":"10.1136\/jitc-2021-002852"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Khalifa AM, Nakamura T, Sato Y, Sato T, Hyodo M, Hayakawa Y, Harashima H. Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody. <i>Int. J. Pharm.<\/i>, <b>624<\/b>, 122034 (2022).","DOI":"10.1016\/j.ijpharm.2022.122034"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Nakamura T, Sasaki S, Sato Y, Harashima H. Cancer immunotherapy with lipid nanoparticles loaded with a stimulator of interferon genes agonist against renal tumor lung metastasis. <i>Pharmaceutics<\/i>, <b>16<\/b>, 31 (2023).","DOI":"10.3390\/pharmaceutics16010031"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Khalifa AM, Nakamura T, Sato Y, Harashima H. Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis <i>via<\/i> the induction of CD11b<sup>high<\/sup>CD27<sup>low<\/sup> memory-like NK cells. <i>Exp. Hematol. Oncol.<\/i>, <b>13<\/b>, 36 (2024).","DOI":"10.1186\/s40164-024-00502-w"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Endo R, Ueda T, Nagaoki T, Shima N, Sato Y, Harashima H, Nakamura T. Impact of <i>in vivo<\/i> fate of STING agonist-loaded lipid nanoparticles on antitumor immunity. <i>J. Control. Release<\/i>, <b>372<\/b>, 609\u2013618 (2024).","DOI":"10.1016\/j.jconrel.2024.06.064"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Endo R, Ueda T, Nagaoki T, Sato Y, Maishi N, Hida K, Harashima H, Nakamura T. Selective vascular disrupting therapy by lipid nanoparticle-mediated Fas ligand silencing and stimulation of STING. <i>Biomaterials<\/i>, <b>321<\/b>, 123297 (2025).","DOI":"10.1016\/j.biomaterials.2025.123297"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nagaoki T, Endo R, Ueda T, Sato Y, Yamada Y, Nakamura T. Effect of vascular disrupting therapy by lipid nanoparticles on the tumor microenvironment. <i>Int. J. Pharm.<\/i>, <b>699<\/b>, 126988 (2026).","DOI":"10.1016\/j.ijpharm.2026.126988"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Fidler IJ. The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited. <i>Nat. Rev. Cancer<\/i>, <b>3<\/b>, 453\u2013458 (2003).","DOI":"10.1038\/nrc1098"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, Psaila B, Kaplan RN, Bromberg JF, Kang Y, Bissell MJ, Cox TR, Giaccia AJ, Erler JT, Hiratsuka S, Ghajar CM, Lyden D. Pre-metastatic niches: organ-specific homes for metastases. <i>Nat. Rev. Cancer<\/i>, <b>17<\/b>, 302\u2013317 (2017).","DOI":"10.1038\/nrc.2017.6"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Sato Y, Hashiba K, Sasaki K, Maeki M, Tokeshi M, Harashima H. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs <i>in vivo<\/i>. <i>J. Control. Release<\/i>, <b>295<\/b>, 140\u2013152 (2019).","DOI":"10.1016\/j.jconrel.2019.01.001"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Warashina S, Nakamura T, Sato Y, Fujiwara Y, Hyodo M, Hatakeyama H, Harashima H. A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells. <i>J. Control. Release<\/i>, <b>225<\/b>, 183\u2013191 (2016).","DOI":"10.1016\/j.jconrel.2016.01.042"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Singh B, Fu C, Bhattacharya J. Vascular expression of the \u03b1<sub>v<\/sub>\u03b2<sub>3<\/sub>-integrin in lung and other organs. <i>Am. J. Physiol. Lung Cell. Mol. Physiol.<\/i>, <b>278<\/b>, L217\u2013L226 (2000).","DOI":"10.1152\/ajplung.2000.278.1.L217"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Liu Z, Wang F, Chen X. Integrin \u03b1<sub>v<\/sub>\u03b2<sub>3<\/sub>-targeted cancer therapy. <i>Drug Dev. Res.<\/i>, <b>69<\/b>, 329\u2013339 (2008).","DOI":"10.1002\/ddr.20265"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Scheepers MRW, van IJzendoorn LJ, Prins MWJ. Multivalent weak interactions enhance selectivity of interparticle binding. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>117<\/b>, 22690\u201322697 (2020).","DOI":"10.1073\/pnas.2003968117"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Woythe L, Porciani D, Harzing T, van Veen S, Burke DH, Albertazzi L. Valency and affinity control of aptamer-conjugated nanoparticles for selective cancer cell targeting. <i>J. Control. Release<\/i>, <b>355<\/b>, 228\u2013237 (2023).","DOI":"10.1016\/j.jconrel.2023.01.008"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. <i>CA Cancer J. Clin.<\/i>, <b>72<\/b>, 7\u201333 (2022).","DOI":"10.3322\/caac.21708"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Naito S, Yamamoto N, Takayama T, <i>et al.<\/i> Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. <i>Eur. Urol.<\/i>, <b>57<\/b>, 317\u2013326 (2010).","DOI":"10.1016\/j.eururo.2008.12.026"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>111<\/b>, 11774\u201311779 (2014).","DOI":"10.1073\/pnas.1410626111"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Salembier R, De Haes C, Demeyere K, Van Laere S, Cervenkova L, Van Renne N, Sotiriou C, Meyer E, Steenbrugge J. Tractable mouse TNBC models capture the heterogeneous tumor immune microenvironment and adaptation to PD-L1 blockade. <i>NPJ Breast Cancer<\/i>, <b>12<\/b>, 15 (2025).","DOI":"10.1038\/s41523-025-00880-2"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Black M, Barsoum IB, Truesdell P, Cotechini T, Macdonald-Goodfellow SK, Petroff M, Siemens DR, Koti M, Craig AW, Graham CH. Activation of the PD-1\/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. <i>Oncotarget<\/i>, <b>7<\/b>, 10557\u201310567 (2016).","DOI":"10.18632\/oncotarget.7235"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Sata M, Walsh K. TNF\u03b1 regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. <i>Nat. Med.<\/i>, <b>4<\/b>, 415\u2013420 (1998).","DOI":"10.1038\/nm0498-415"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F, Coukos G. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. <i>Nat. Med.<\/i>, <b>20<\/b>, 607\u2013615 (2014).","DOI":"10.1038\/nm.3541"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/10\/49_b26-00306\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:25:46Z","timestamp":1790997946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/10\/49_b26-00306\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00306","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"b26-00306"}}